Shopping Cart
- Remove All
- Your shopping cart is currently empty
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $169 | In Stock | |
2 mg | $249 | In Stock | |
5 mg | $426 | In Stock | |
10 mg | $683 | In Stock | |
25 mg | $997 | In Stock |
Description | Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. |
In vitro | Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin.As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin[1]. |
Cas No. | 189261-10-7 |
Relative Density. | no data available |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.